DB00005 in the treatment of rheumatoid arthritis . DB00005 ( DB01613 ) is the first anti-tumor necrosis factor ( P01375 ) agent to be approved for the treatment of rheumatoid arthritis ( RA ) . Over the last 8 years , several clinical trials have shown its efficacy and safety in established and early RA , as well as a monotherapy or in combination with methotrexate . DB01613 not only reduces the signs and symptoms of RA , but also retards the progression of radiographic damage and improves the quality of life and function of patients . Its safety profile has been predictable since the first clinical trials with no new major safety concerns . Beyond its efficacy in RA , DB01613 is also indicated for the treatment of psoriatic arthritis . This current report reviews the evidence and the data in RA and psoriatic arthritis ( PsA ) .